Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | ADA | P00813 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | RIN1 | Q13671 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2113420 | 1.00 | ALDH1A1 (0.48) | ALDH1A1LMNAALBMAPK1NR2F2 | |
| SCHEMBL887896 | 0.88 | ALDH1A1 (0.51) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| SCHEMBL9601775 | 0.79 | ALDH1A1 (0.60) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| SCHEMBL3683208 | 0.76 | ALDH1A1 (0.60) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| SCHEMBL12149460 | 0.76 | ALDH1A1 (0.60) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| SCHEMBL23254277 | 0.76 | ALDH1A1 (0.60) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| SCHEMBL18410860 | 0.75 | MAPK1 (0.60) | ALDH1A1LMNAALBMAPK1NR2F2 | |
| Didanosine SCHEMBL29387997 | 0.74 | ALDH1A1 (0.61) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| Didanosine SCHEMBL1769151 | 0.74 | ALDH1A1 (0.61) | ALDH1A1LMNAALBMAPK1CYP1A2 | |
| Didanosine SCHEMBL12150307 | 0.74 | ALDH1A1 (0.61) | ALDH1A1LMNAALBMAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158770-B2 | Content dependent inhibitors of cytidine deaminases and uses thereof | UNIVERSITY OF ROCHESTER (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | DCTD, CDA, ADA | ALDH1A1 1171/4885LMNA 2870/4885ALB 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.